IFRX

InflaRx NV Stock Price

3.66
0.00 (0.0%)
3.66

Low
3.50

52 Week Range

High
9.70

Best deals to access real time data!
Big Cap Pro
Monthly Subscription
for only
$52.04
Small Cap Pro
Monthly Subscription
for only
$49.05
DDE w/Realtime (Monthly)
Monthly Subscription
for only
$34.10
VAT not included
Company Name Stock Ticker Symbol Market Type
InflaRx NV IFRX NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
0.00 0.0% 3.66 04:00:00
Open Price Low Price High Price Close Price Prev Close
3.66
Bid Price Ask Price Spread News
3.50 3.73 0.23 - -
Last Trade Time Type Quantity Stock Price Currency
- 0 $ 3.66 USD

InflaRx NV Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 103.32M 28.23M 23.88M $ - $ - -2.36 -3.20
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - 0.00% - -

more financials information »

InflaRx NV News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical IFRX Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week3.863.903.513.70246,193-0.20-5.18%
1 Month4.264.343.513.80276,645-0.60-14.08%
3 Months5.806.383.514.65395,329-2.14-36.9%
6 Months4.656.883.514.80333,262-0.99-21.29%
1 Year5.079.703.505.56531,124-1.41-27.81%
3 Years39.0053.102.176.53539,772-35.34-90.62%
5 Years15.1953.102.176.85480,259-11.53-75.91%

InflaRx NV Description

InflaRx NV is a clinical-stage biopharmaceutical company is focused on applying proprietary anti-C5a technology to discover and develop specific inhibitors of the complement activation factor known as C5a. The lead product candidate of the company is IFX-1, which is developed for the treatment of Hidradenitis Suppurativa, a rare and chronic debilitating systemic inflammatory skin disease. The company's proprietary anti-C5a technology is an inflammatory mediator involved in the progression of a variety of autoimmune and other inflammatory diseases. It is also developing IFX-1 for the treatment of AAV, a life-threatening autoimmune disease associated with powerful inflammatory flares that impair kidney function and lead to fatal organ dysfunction.


Your Recent History
NASDAQ
IFRX
InflaRx NV
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.